Zuellig Pharma Strengthens Clinical Sourcing Capabilities in China through Strategic Acquisition
The acquisition of our newly licensed Hangzhou facility establishes robust local sourcing capabilities to accelerate and support clinical trials across China HANGZHOU, China, Nov. 3, 2026 /PRNewswire/ -- Zuellig Pharma, a leading healthcare solutions company in Asia, announced the...
Covered in this story
Call it yourself
No calls on $NOV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on NOV →Dalsna Finance is currently tracking 124 stories mentioning NOV, the earliest published 26 Oct 2026.
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.